Drug Utilization Review (DUR) Meeting Minutes
June 1, 2009

Members Present: Patricia Churchill, Norman Byers, Carrie Sorenson, Greg Pfister, Kim Krohn, Jeffrey Hostetter, John Savageau, Scott Setzepfandt, Leeann Ness, Carlotta McCleary, Cheryl Huber, Gary Betting
Members Absent: Steve Irsfeld, Todd Twogood
Medicaid Pharmacy Department: Brendan Joyce
HID Staff Present: Candace Rieth

Chair, C. Sorenson called the meeting to order at 1:09 pm. Chair, C. Sorenson asked for a motion to approve the minutes from the March meeting. J. Hostetter moved that the minutes be approved and N. Byers seconded the motion. Chair, C. Sorenson called for a voice vote to approve the minutes. The motion passed with no audible dissent.

Synagis Annual Review
B. Joyce reviewed Synagis utilization for the 2008-2009 RSV season. The season ran from October 15th through April 20th. For the 2009-2010 Synagis season, the department would like to make the enrollment process web-based. RSV treatment guidelines will be reviewed and incorporated into the enrollment process.

Budget Update
B. Joyce stated that the budget approved during the legislative session is $50,168,148 for the next biennium. Medicaid enrollment is approximately 54,000 and approximately 33% receive prescriptions.

Provider Mailings
At the March meeting, Board members requested that two letters be mailed to providers informing them of the tablet splitting initiative as well as the ADHD dose optimization initiative. C. Rieth informed the Board that 463 letters were sent to providers of medications used to treat ADHD and 150 tablet splitting letters were sent.

Aczone Second Review
At the March meeting a motion was made to prior authorize Aczone. Chair, C. Sorenson called for a voice vote. Motion passed with no audible dissent.

Yearly PA Review
The Board reviews products annually that have previously been placed on prior authorization. This allows the Board a chance to update the prior authorization forms and criteria. Sedative/Hypnotics, Qualaquin, ACE-Is/ARBs/Renin Inhibitors, Synagis, and Growth Hormones were reviewed. The following recommendations were made: Add a checkbox and criteria for Sedative/Hypnotics that states 'high risk for addiction' and combine the ACE-Is/ARBs/Renin Inhibitors on one form.

Legislative Update
B. Joyce gave the legislative update. House Bill 1385 was the bill that would make current restrictions on certain classes of medications permanent. The Senate and House both voted to make the restrictions permanent and the governor signed the bill. Classes of medication affected by this bill include antipsychotics, antidepressants, anticonvulsants, antiretrovirals, antineoplastics and stimulant medication used for the treatment of attention deficit disorder and attention deficit hyperactivity disorder.

Another change made to House Bill 1385 was the addition of a pharmacist or physician representing the generic pharmaceutical industry to the DUR Board.

Uloric Review
B. Joyce reviewed Uloric with Board members. Scott Kelsen spoke on behalf of Takeda, manufacturer of Uloric. K. Krohn made a motion to include renal and hepatic impairment as a criterion for approval of Uloric. N. Byers seconded the motion. Chair, C. Sorenson called for a voice vote. The motion passed with no audible dissent. J. Hostetter made a motion that serum uric acid level be removed from the Uloric prior authorization form and the failed trial be reduced from 3 months to 1 month. G. Pfister seconded the motion. Chair, C. Sorenson called for a voice vote. The motion passed with no audible dissent. P. Churchill made a motion to prior authorize Uloric with the amended changes. G. Pfister seconded the motion. This topic will be brought up again at the next Board meeting for finalization.

Moxatag Review
B. Joyce reviewed Moxatag with Board members. There was no public comment. J. Savageau made a motion to prior authorize Moxatag. C. Huber seconded the motion. This topic will be brought up again at the next Board meeting for finalization.

Savella Review
B. Joyce reviewed Savella with Board members. Tobie Escher spoke on behalf of Forest Pharmaceuticals, manufacturer of Savella. After much discussion, the Board recommended that the prior authorization of Savella be tabled.

Targeted Immune Modulators
B. Joyce reviewed targeted immune modulators with the Board members. Jonathan Holt spoke on behalf of UCB, manufacturer of Cimzia. Hoa Pham spoke on behalf of Amgen, manufacturer of Enbrel. J. Hostetter made a motion to place targeted immune modulators on prior authorization. G. Pfister seconded the motion. This topic will be brought up again at the next Board meeting for finalization.

Criteria Recommendations
The recommended RDUR criteria enclosed in the packet were developed from product information provided by the manufacturers and usually are consistent with new indications, new drugs added, new warnings, etc. These proposed criteria will be added to the current set of criteria, and will be used in future DUR cycles. J. Savageau moved to approve the new criteria and G. Pfister seconded the motion. Chair, C. Sorenson called for a voice vote. The motion passed with one audible dissent.

The next DUR board meeting will be held September 14, 2009. J. Hostetter made a motion to adjourn the meeting into executive session to review patient profiles. N. Byers seconded. The motion passed with no audible dissent. Chair C. Sorenson adjourned the meeting at 2:55 pm.

Executive Session
Chair C. Sorenson called the executive session to order at 3:10. DUR Board members reviewed patient profiles and physician responses generated from the low dose antipsychotic mailing. The executive session was adjourned at 3:30 pm.